Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive care unit and cardiac surgery.</li><li>The company also seeks U.S. and Canadian approval of a second product, DrugSorb-ATR, to reduce perioperative bleeding risk in patients on the blood thinner, ticagrelor, undergoing cardiac surgery.</li><li>Data from the pivotal U.S. STAR-T trial presented at the AATS conference and recent KOL/Analyst/Investor day demonstrate a favorable benefit-to-risk profile of DrugSorb-ATR to reduce serious bleeding in patients undergoing isolated CABG. Company plans to submit for FDA De Novo and Health Canada marketing approvals in Q3 2024.</li></ul>

CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive care unit and cardiac surgery.The company also seeks U.S. and Canadian approval of a second product, DrugSorb-ATR, to reduce perioperative bleeding risk in patients on the blood thinner, ticagrelor, undergoing cardiac surgery.Data from the pivotal U.S. STAR-T trial presented at the AATS conference and recent KOL/Analyst/Investor day demonstrate a favorable benefit-to-risk profile of DrugSorb-ATR to reduce serious bleeding in patients undergoing isolated CABG. Company plans to submit for FDA De Novo and Health Canada marketing approvals in Q3 2024.

CTSO: CytoSorbents reports 1st quarter 2024 financial results and highlighted STAR-T trial data presentation at the AATS conference.